Stockreport

New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease [Yahoo! Fina...

Lexicon Pharmaceuticals, Inc.  (LXRX) 
Last lexicon pharmaceuticals, inc. earnings: 4/27 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: lexpharma.com/investors
PDF clinical data from its inTandem3 Phase 3 trial demonstrated that treatment with sotagliflozin resulted in improved glycemic control in patients with type 1 diabetes and [Read more]